DDInter1003 DDInter1376
Ixekizumab is a humanized immunoglobulin G subclass 4 (IgG4) monoclonal antibody (mAb) against interleukin-17A (IL-17A) and prevents it from interacting with the IL-17A receptor. As IL-17A is a pro-inflammatory cytokine involved in inflammation and immune responses, blocking its effect is beneficial for use in inflammatory conditions. In particular, IL-17A has been found to be implicated in a variety of autoimmune diseases including Rheumatoid Arthritis and plaque psoriasis. Ixekizumab is produced by recombinant DNA technology in a recombinant mammalian cell line and purified using standard technology for bioprocessing. Ixekizumab is comprised of two identical light chain polypeptides of 219 amino acids each and two identical heavy chain polypeptides of 445 amino acids each, and has a molecular weight of 146,158 Daltons for the
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Ixekizumab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zinc sulfate
Ixekizumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lidocaine
Ixekizumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Hepatitis B Vaccine (Recombinant)
Ixekizumab {u} may lead to a major life threatening interaction when taken with {v} Etanercept
Ixekizumab {u} may lead to a major life threatening interaction when taken with {v} Upadacitinib
Ixekizumab may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate
Ixekizumab may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine
Ixekizumab may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant)
Ixekizumab may lead to a major life threatening interaction when taken with Etanercept
Ixekizumab may lead to a major life threatening interaction when taken with Upadacitinib